Primary amyloidosis differential diagnosis: Difference between revisions

Jump to navigation Jump to search
Line 5: Line 5:
==Overview==
==Overview==


==Differentiating Primary amyloidosis from Other Diseases==
* Differentiating Primary amyloidosis from Other Diseases
 
{|
{|
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Organ System Involvement}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Organ System Involvement}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Differential Diagnosis}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Causes}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Causes}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Clinical Features}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Clinical Features}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Laboratory Findings}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Gold Standard Test}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Therapy}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Therapy}}
|-
|-
! rowspan="8" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Nephrotic Syndrome and Real Failure
! rowspan="8" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Nephrotic Syndrome and Real Failure
Line 41: Line 42:
* Proteinuria
* Proteinuria
* Urinary hyaline and fatty casts
* Urinary hyaline and fatty casts
*Hypercholesterolemia


*
*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Biopsy:
* Biopsy:
 
** Diffuse glomerular deposition of amorphous hyaline material (nodular pattern), in mesangium (weakly staining with periodic acid-Schiff (PAS)
* Diffuse glomerular deposition of amorphous hyaline material (nodular pattern), in mesangium (weakly staining with periodic acid-Schiff (PAS)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Diabetic Nephropathy
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Diabetic Nephropathy
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Hyperfiltration
* Constriction of efferent arteriole
* Microalbuminuria
* Mesangial proliferation
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Nocturia
* Fatigue
* Pruritis
* Peripheral edema
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Hyperglycemia (random plasma glucose ≥200 mg/dL)
* Proteinuria
* Glucosuria
* HbA1C ≥6.5% (48 mmol/mol). <br />
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Biopsy:
** PAS positive Kimmelstiel-Wilson nodules
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Minimal Change Disease
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |Minimal Change Disease
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Upper respiratory tract infection
* Allergy to bee sting
* NSAID
* Gold
* Penicillamine
* Ampicillin
* Mercury
* Hodgkin's and non-Hodgkin's lymphoma
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 98: Line 121:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Organ System Involvement}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Organ System Involvement}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Differential Diagnosis}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Differential Diagnosis}}
! style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Causes}}
! style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Causes}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF| Clinical Features}}
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF| Clinical Features}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Laboratory Findings}}
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Laboratory Findings}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Gold Standard Test}}
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Gold Standard Test}}
! style="background: #4479BA; width: 300px;" | {{fontcolor|#FFF|Therapy}}
! style="background: #4479BA; width: 300px;" |{{fontcolor|#FFF|Therapy}}
|-
|-
| rowspan="6" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Polyneuropathy'''''
| rowspan="6" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Polyneuropathy'''''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''POEMS syndrome (Demyelinating)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''POEMS syndrome (Demyelinating)'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Monoclonal]] [[plasma cell]] proliferation  
*[[Monoclonal]] [[plasma cell]] proliferation
* Cytokine storm (IL-1, IL-6, IL-12, TNF alpha, VEGF)
* Cytokine storm (IL-1, IL-6, IL-12, TNF alpha, VEGF)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Symmetrical, ascending chronic progressive [[polyneuropathy]] with both [[Sensory system|sensory]] (pin-prick and vibration) and [[Motor skill|motor]] disability ([[Motor skill|motor]] > [[sensory]])
* Symmetrical, ascending chronic progressive [[polyneuropathy]] with both [[Sensory system|sensory]] (pin-prick and vibration) and [[Motor skill|motor]] disability ([[Motor skill|motor]] > [[sensory]])
* Generalized/extermity [[pain]]
* Generalized/extermity [[pain]]
* [[Areflexia]]
*[[Areflexia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
*Increased number of [[Platelet|thrombocytes]]
*Increased number of [[Platelet|thrombocytes]]
Line 125: Line 148:
*Elevated levels of antitiroglobulin [[antibody]] and antithyroid peroxydase [[antibody]]
*Elevated levels of antitiroglobulin [[antibody]] and antithyroid peroxydase [[antibody]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[POEMS syndrome diagnostic criteria|International Myeloma Working Group (IMWG) clinical and laboratory diagnostic criteria]]
*[[POEMS syndrome diagnostic criteria|International Myeloma Working Group (IMWG) clinical and laboratory diagnostic criteria]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Metabolic syndrome|Metabolic Syndrome]] (Axonal pathology)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Metabolic syndrome|Metabolic Syndrome]] (Axonal pathology)'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Diabetes mellitus]]
*[[Diabetes mellitus]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Symmetric sensorimotor distal polyneuropathy
* Symmetric sensorimotor distal polyneuropathy
* Asymmetric proximal neuropathy
* Asymmetric proximal neuropathy
* [[Oculomotor nerve palsy|3rd nerve palsy]]
*[[Oculomotor nerve palsy|3rd nerve palsy]]
* [[Carpal tunnel syndrome|Carpel tunnel syndrome]]
*[[Carpal tunnel syndrome|Carpel tunnel syndrome]]
* [[Autonomic neuropathy]]
*[[Autonomic neuropathy]]
* "Glove and stocking" type pain
* "Glove and stocking" type pain
* [[Muscle wasting]]
*[[Muscle wasting]]
* [[Hammer toe|Hammer toes]]
*[[Hammer toe|Hammer toes]]
* [[Polyuria]]
*[[Polyuria]]
* [[Polydipsia]]
*[[Polydipsia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Uncontrolled [[hyperglycemia]]
* Uncontrolled [[hyperglycemia]]
* Slowed [[Nerve conduction study|nerve conduction]]
* Slowed [[Nerve conduction study|nerve conduction]]
* [[Small fiber peripheral neuropathy|Small fiber dysfunction]]
*[[Small fiber peripheral neuropathy|Small fiber dysfunction]]
* [[Monofilament|Monofilament testing]]
*[[Monofilament|Monofilament testing]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Fasting blood sugar|Fasting blood sugar level]] greater than equal to 126 mg/dl on 2 separate occasions
*[[Fasting blood sugar|Fasting blood sugar level]] greater than equal to 126 mg/dl on 2 separate occasions
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Diabetes mellitus medical therapy|Anti-diabetic therapy]]
*[[Diabetes mellitus medical therapy|Anti-diabetic therapy]]
* [[Gabapentin]]
*[[Gabapentin]]
* [[Carbamazepine]]
*[[Carbamazepine]]
* [[Foot care]]
*[[Foot care]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Vitamin deficiencies|Vitamin Deficiencies]] (Axonal Pathology)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Vitamin deficiencies|Vitamin Deficiencies]] (Axonal Pathology)'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Vitamin B12 deficiency]] (Decreased [[S-Adenosyl methionine|S-adenosyl methionine]])
*[[Vitamin B12 deficiency]] (Decreased [[S-Adenosyl methionine|S-adenosyl methionine]])
* [[Thiamine deficiency|Vitamin B1 deficiency]]
*[[Thiamine deficiency|Vitamin B1 deficiency]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Primarily [[sensory]] deficits
* Primarily [[sensory]] deficits
* Vibration and [[proprioception]] affected
* Vibration and [[proprioception]] affected
* [[Gait abnormality|Gait abnormalities]]
*[[Gait abnormality|Gait abnormalities]]
* [[Cognitive impairment]]
*[[Cognitive impairment]]
* [[Irritability]]
*[[Irritability]]
* [[Glossitis]]
*[[Glossitis]]


*
*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Anemia]] ([[Megaloblastic Anemias|megaloblastic]] in case of [[Vitamin B12 deficiency|B12 deficiency]])
*[[Anemia]] ([[Megaloblastic Anemias|megaloblastic]] in case of [[Vitamin B12 deficiency|B12 deficiency]])
* Decreased [[serum]] [[Vitamin B12]] levels (< 200 pg/ml)
* Decreased [[serum]] [[Vitamin B12]] levels (< 200 pg/ml)
* [[Methylmalonic acidemia|Elevated methylmalonic acid]]
*[[Methylmalonic acidemia|Elevated methylmalonic acid]]
*  
*  
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Serum]] [[Vitamin B12]] levels
*[[Serum]] [[Vitamin B12]] levels
* [[Methylmalonic acid|Methylmalonic acid levels]]
*[[Methylmalonic acid|Methylmalonic acid levels]]
* [[Intrinsic factor|Intrinsic factor antibodies]]
*[[Intrinsic factor|Intrinsic factor antibodies]]


*
*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Vitamin B12]] supplement ([[parenteral]])
*[[Vitamin B12]] supplement ([[parenteral]])
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Guillain-Barré syndrome|Guillain-Barre Syndrome]] (Demyelinating)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Guillain-Barré syndrome|Guillain-Barre Syndrome]] (Demyelinating)'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Anti-ganglioside antibodies|Anti-ganglioside]] and anti-[[myelin]] antibodies
*[[Anti-ganglioside antibodies|Anti-ganglioside]] and anti-[[myelin]] antibodies
* [[Viral]] infections:
*[[Viral]] infections:
**[[Epstein Barr virus]]
**[[Epstein Barr virus]]
** [[Human Immunodeficiency Virus (HIV)|HIV]]
**[[Human Immunodeficiency Virus (HIV)|HIV]]
** [[Cytomegalovirus]]
**[[Cytomegalovirus]]
** [[Varicella Zoster Virus|Varicella Zoster virus]]
**[[Varicella Zoster Virus|Varicella Zoster virus]]
* [[Bacterial]] infections:
*[[Bacterial]] infections:
**[[Campylobacter]] infection
**[[Campylobacter]] infection
** [[Mycoplasma pneumoniae]]
**[[Mycoplasma pneumoniae]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Rapid onset and quick progression
* Rapid onset and quick progression
* Progression stops after 2-3 weeks
* Progression stops after 2-3 weeks
* Bilateral ascending [[Paraesthesia|paraesthesias]] and [[paralysis]] (generalized)
* Bilateral ascending [[Paraesthesia|paraesthesias]] and [[paralysis]] (generalized)
* [[Muscle weakness|Weakness]]
*[[Muscle weakness|Weakness]]
* [[Ataxia]]
*[[Ataxia]]
* [[Areflexia]]
*[[Areflexia]]
* No fever
* No fever
* 4 sub-types:
* 4 sub-types:
Line 212: Line 235:
* Clinical diagnostic criteria (progressive weakness of more than two [[limbs]], [[areflexia]], and progression for no more than four weeks)
* Clinical diagnostic criteria (progressive weakness of more than two [[limbs]], [[areflexia]], and progression for no more than four weeks)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Intravenous]] [[immunoglobulins]]
*[[Intravenous]] [[immunoglobulins]]
* [[Plasma]] exchange
*[[Plasma]] exchange
* [[Mechanical ventilation|Respiratory support]]
*[[Mechanical ventilation|Respiratory support]]
* [[DVT]]/[[PE]] [[prevention]]
*[[DVT]]/[[PE]] [[prevention]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic inflammatory demyelinating polyneuropathy|Chronic Inflammatory Demyelinating Polyneuropathy]] (CIDP) (Mixed axonal and demyelinatiing)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic inflammatory demyelinating polyneuropathy|Chronic Inflammatory Demyelinating Polyneuropathy]] (CIDP) (Mixed axonal and demyelinatiing)'''
Line 224: Line 247:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Slow onset and gradual progression
* Slow onset and gradual progression
* [[Relapse|Relapsing]] and remitting course
*[[Relapse|Relapsing]] and remitting course
* Symmetrical [[Proximal muscle weakness|proximal]] and [[Distal muscle weakness|distal motor]] and [[Sensory system|sensory weakness]] (legs>arms)
* Symmetrical [[Proximal muscle weakness|proximal]] and [[Distal muscle weakness|distal motor]] and [[Sensory system|sensory weakness]] (legs>arms)
* [[Foot drop]]
*[[Foot drop]]
* [[Numbness]], [[tingling]] and [[pain]]
*[[Numbness]], [[tingling]] and [[pain]]
* [[Areflexia]]
*[[Areflexia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Elevated [[CSF]] [[protein]] ([[oligoclonal bands]] with normal [[White blood cells|WBCs]])
* Elevated [[CSF]] [[protein]] ([[oligoclonal bands]] with normal [[White blood cells|WBCs]])
Line 234: Line 257:
* Prolonged distal [[Motor skill|motor]] latencies (period between F wave and initial stimulation)
* Prolonged distal [[Motor skill|motor]] latencies (period between F wave and initial stimulation)
* Delayed F wave latencies (recorded from the [[feet]], hence called "F" waves)
* Delayed F wave latencies (recorded from the [[feet]], hence called "F" waves)
* [[MRI]] contrast enhancement and enlargement of [[Vertebra|T2]] [[spinal segments]]
*[[MRI]] contrast enhancement and enlargement of [[Vertebra|T2]] [[spinal segments]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* EFNS/PNS criteria
* EFNS/PNS criteria
* Koski criteria
* Koski criteria
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Corticosteroids]]
*[[Corticosteroids]]
* [[Intravenous immunoglobulin]] ([[IVIG]])
*[[Intravenous immunoglobulin]] ([[IVIG]])
* [[Immunosupressive drug|Immunosupressants]] ([[Alemtuzumab|Alemtuzemab]] [[Azathioprine]] [[Cyclophosphamide]] [[Cyclosporine|Cyclosporin]] [[Etanercept]] [[Interferon-alpha]])
*[[Immunosupressive drug|Immunosupressants]] ([[Alemtuzumab|Alemtuzemab]] [[Azathioprine]] [[Cyclophosphamide]] [[Cyclosporine|Cyclosporin]] [[Etanercept]] [[Interferon-alpha]])
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multifocal motor neuropathy|Multifocal Motor Neuropathy]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Multifocal motor neuropathy|Multifocal Motor Neuropathy]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Immune response|Abnormal immune response]] ([[Anti-ganglioside antibodies|Anti ganglioside]] [[Anti-ganglioside antibodies|GM-1]] [[IgM]] [[antibodies]])
*[[Immune response|Abnormal immune response]] ([[Anti-ganglioside antibodies|Anti ganglioside]] [[Anti-ganglioside antibodies|GM-1]] [[IgM]] [[antibodies]])
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Progressive, asymmetric, distal and upper [[Limb (anatomy)|limb]] predominant weakness
* Progressive, asymmetric, distal and upper [[Limb (anatomy)|limb]] predominant weakness
* No significant [[sensory]] abnormalities
* No significant [[sensory]] abnormalities
* [[Areflexia]]
*[[Areflexia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Elevated [[CSF]] [[protein]]
* Elevated [[CSF]] [[protein]]
Line 260: Line 283:
*
*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Intravenous immunoglobulin|Intravenous immunoglobulins]]
*[[Intravenous immunoglobulin|Intravenous immunoglobulins]]
* [[Cyclophosphamide]]
*[[Cyclophosphamide]]
* [[Rituximab]]
*[[Rituximab]]
|-
|-
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Organ System Involvement'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Organ System Involvement'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Differential Diagnosis'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Causes'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Causes'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Features'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Features'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Laboratory Findings}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Gold Standard Test}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Therapy'''}}
|-
|-
| rowspan="7" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)'''''
| rowspan="7" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Organomegaly (Hepatosplenomegaly and Lymphadenopathy)'''''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Malaria]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Malaria]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Plasmodium falciparum]]
*[[Plasmodium falciparum]]
* [[Plasmodium ovale|P. ovale]]
*[[Plasmodium ovale|P. ovale]]
* [[P. malariae]]
*[[P. malariae]]
* [[Plasmodium knowlesi|P. knowlesi]]  
*[[Plasmodium knowlesi|P. knowlesi]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Tertian ([[Plasmodium vivax|vivax]], [[Plasmodium ovale|ovale]], [[Plasmodium falciparum|falciparum]]), quartan (malariae), quotidian fever ([[Plasmodium knowlesi|knowlesi]])
* Tertian ([[Plasmodium vivax|vivax]], [[Plasmodium ovale|ovale]], [[Plasmodium falciparum|falciparum]]), quartan (malariae), quotidian fever ([[Plasmodium knowlesi|knowlesi]])
* [[Vector]] is female [[Anopheles]] mosquito
*[[Vector]] is female [[Anopheles]] mosquito
* [[Hepatosplenomegaly]]
*[[Hepatosplenomegaly]]
* [[Lymphadenopathy]]
*[[Lymphadenopathy]]
* [[Jaundice]]
*[[Jaundice]]
* [[Icterus (medicine)|Icterus]]
*[[Icterus (medicine)|Icterus]]
* [[Tachycardia]]
*[[Tachycardia]]
* [[Tachypnea]]
*[[Tachypnea]]
* [[Productive cough]]
*[[Productive cough]]
* [[Hematuria]]
*[[Hematuria]]
* [[Altered mental status]]
*[[Altered mental status]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Microcytic anemia]]
*[[Microcytic anemia]]
* [[Malaria differential diagnosis|Thick and thin blood films]] ([[Giemsa stain|Giemsa staining]])
*[[Malaria differential diagnosis|Thick and thin blood films]] ([[Giemsa stain|Giemsa staining]])


* Rapid diagnostic test ([[antigen]] detection
* Rapid diagnostic test ([[antigen]] detection
* [[Polymerase chain reaction]] ([[Polymerase chain reaction|PCR]])
*[[Polymerase chain reaction]] ([[Polymerase chain reaction|PCR]])
* [[Enzyme linked immunosorbent assay (ELISA)|Enzyme linked immunosorbent assay]] ([[Enzyme linked immunosorbent assay (ELISA)|ELISA]])
*[[Enzyme linked immunosorbent assay (ELISA)|Enzyme linked immunosorbent assay]] ([[Enzyme linked immunosorbent assay (ELISA)|ELISA]])
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Malaria differential diagnosis|Thick and thin films]]
*[[Malaria differential diagnosis|Thick and thin films]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Non-[[Plasmodium falciparum|falciparum]] species:
* Non-[[Plasmodium falciparum|falciparum]] species:
** [[Chloroquine]] (in susceptible)
**[[Chloroquine]] (in susceptible)
** [[Artemisinin]] plus [[Mefloquine|mefloquin]] or [[lumefantrine]] (in [[chloroquine]] resistant)
**[[Artemisinin]] plus [[Mefloquine|mefloquin]] or [[lumefantrine]] (in [[chloroquine]] resistant)
* [[Plasmodium falciparum|Falciparum]] species:
*[[Plasmodium falciparum|Falciparum]] species:
** [[Chloroquine]] (in susceptible)
**[[Chloroquine]] (in susceptible)
** [[Artemether]] plus [[lumefantrine]] (in [[Chloroquine|chloroquin]] resistant) OR
**[[Artemether]] plus [[lumefantrine]] (in [[Chloroquine|chloroquin]] resistant) OR
** [[Artesunate]] plus [[Mefloquine|mefloquin]] OR
**[[Artesunate]] plus [[Mefloquine|mefloquin]] OR
** [[Artesunate]] plus [[Sulfadoxine|sulfadoxine-pyrimethamine]]
**[[Artesunate]] plus [[Sulfadoxine|sulfadoxine-pyrimethamine]]
** [[Atovaquone-Proguanil|Atovaquone plus proguanil]]
**[[Atovaquone-Proguanil|Atovaquone plus proguanil]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Kala-azar]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Kala-azar]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Leishmaniasis|Leshmania donovani]]
*[[Leishmaniasis|Leshmania donovani]]
* L. infantum
* L. infantum
* L. chagasi
* L. chagasi
Line 319: Line 342:
*
*
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Fever]]
*[[Fever]]
* Vector is [[sandfly]]
* Vector is [[sandfly]]
* [[Hepatosplenomegaly]]
*[[Hepatosplenomegaly]]
* [[Lymphadenopathy]]
*[[Lymphadenopathy]]
* [[Hyperpigmentation]]
*[[Hyperpigmentation]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Anemia]]
*[[Anemia]]
* [[Direct agglutination test]] (DAT)
*[[Direct agglutination test]] (DAT)
* rk39 dipstick
* rk39 dipstick
* [[Enzyme linked immunosorbent assay (ELISA)|ELISA]]
*[[Enzyme linked immunosorbent assay (ELISA)|ELISA]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Splenic]] aspiration
*[[Splenic]] aspiration
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Liposomal amphotericin B]]
*[[Liposomal amphotericin B]]
* [[Sodium stibogluconate]]
*[[Sodium stibogluconate]]
* [[Pentamidine]]
*[[Pentamidine]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Hepatitis|Infective Hepatitis]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Hepatitis|Infective Hepatitis]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Hepatitis A virus|Hepatitis A virus (HAV)]]
*[[Hepatitis A virus|Hepatitis A virus (HAV)]]
* [[HBV]]
*[[HBV]]
* [[Hepatitis C|HCV]]
*[[Hepatitis C|HCV]]
* [[Hepatitis D|HDV]] (co-infection with [[HBV]])
*[[Hepatitis D|HDV]] (co-infection with [[HBV]])
* [[Hepatitis E|HEV]]
*[[Hepatitis E|HEV]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Fever]]
*[[Fever]]
* Transmitted via [[fecal-oral route]] ([[Hepatitis A|HAV]], [[Hepatitis B virus|HBV]], [[HDV]], [[HEV]]), infected sera ([[HCV]]), [[sexual contact]] with infected individuals
* Transmitted via [[fecal-oral route]] ([[Hepatitis A|HAV]], [[Hepatitis B virus|HBV]], [[HDV]], [[HEV]]), infected sera ([[HCV]]), [[sexual contact]] with infected individuals
* [[Hepatosplenomegaly]] (may become shrunken in cases of [[cirrhosis]] due to chronic infection)
*[[Hepatosplenomegaly]] (may become shrunken in cases of [[cirrhosis]] due to chronic infection)
* [[Lymphadenopathy]]
*[[Lymphadenopathy]]
* [[Jaundice]]
*[[Jaundice]]
* [[Palmar erythema]]
*[[Palmar erythema]]
* [[Spider angiomata]]
*[[Spider angiomata]]
* [[Gynecomastia]]
*[[Gynecomastia]]
* [[Arthritis-dermatitis syndrome]]
*[[Arthritis-dermatitis syndrome]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Antigen]] and [[antibody]] detection
*[[Antigen]] and [[antibody]] detection
* Total and direct [[bilirubin]] (increased)
* Total and direct [[bilirubin]] (increased)
* Severe disease is often associated with persistent [[bilirubin]] levels >340 mmol/L
* Severe disease is often associated with persistent [[bilirubin]] levels >340 mmol/L
* [[ALT]] and [[AST]] (increased)
*[[ALT]] and [[AST]] (increased)
* [[Alkaline phosphatase]] (normal or mildly elevated)
*[[Alkaline phosphatase]] (normal or mildly elevated)
* [[Prothrombin time]] (prolonged from synthetic defect, caused by hepatocellular [[necrosis]])
*[[Prothrombin time]] (prolonged from synthetic defect, caused by hepatocellular [[necrosis]])
* [[Total protein]] (decreased)
*[[Total protein]] (decreased)
* [[Globulin]] (mildly elevated)
*[[Globulin]] (mildly elevated)
* Initial [[lymphopenia]] and [[neutropenia]], followed by relative [[lymphocytosis]]
* Initial [[lymphopenia]] and [[neutropenia]], followed by relative [[lymphocytosis]]
* [[Anemia|Low hemoglobin]]
*[[Anemia|Low hemoglobin]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Antigen]] and [[antibody]] detection
*[[Antigen]] and [[antibody]] detection
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Interferon]] ([[IFN]])
*[[Interferon]] ([[IFN]])


* [[Antivirals|Nucleoside analogs]]
*[[Antivirals|Nucleoside analogs]]


* [[Antivirals|Nucleotide analogs]]
*[[Antivirals|Nucleotide analogs]]
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic myelogenous leukemia|Chronic Myelogenous Leukemia]] (CML)'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Chronic myelogenous leukemia|Chronic Myelogenous Leukemia]] (CML)'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Philadelphia chromosome|BCR/ABL gene]] fusion product due to [[Chromosomal translocation|translocation]] [[mutation]] [[Philadelphia chromosome|t(9;22)]](q34;q11)
*[[Philadelphia chromosome|BCR/ABL gene]] fusion product due to [[Chromosomal translocation|translocation]] [[mutation]] [[Philadelphia chromosome|t(9;22)]](q34;q11)
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Fever]]
*[[Fever]]
* [[Weight loss]]
*[[Weight loss]]
* [[Hepatosplenomegaly]]
*[[Hepatosplenomegaly]]
* [[Lymphadenopathy]]
*[[Lymphadenopathy]]


* [[Bruises]]
*[[Bruises]]
* [[Petechiae]]
*[[Petechiae]]
* [[Ulcers]]
*[[Ulcers]]
* [[Vesicles]]
*[[Vesicles]]
* [[Malaise]]  
*[[Malaise]]
* [[Early satiety]]
*[[Early satiety]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Anemia]]
*[[Anemia]]


* [[Leukocytosis]] (median of 100,000/µL) with a [[left shift]]
*[[Leukocytosis]] (median of 100,000/µL) with a [[left shift]]
* [[Thrombocytosis]]
*[[Thrombocytosis]]
* [[Blast|Blasts]] usually <2%
*[[Blast|Blasts]] usually <2%
* Absolute [[basophilia]]  
* Absolute [[basophilia]]
* Absolute [[eosinophilia]]
* Absolute [[eosinophilia]]
* [[Monocytosis]]
*[[Monocytosis]]
* [[Thrombocytosis]]
*[[Thrombocytosis]]
* [[Thrombocytopenia]] suggests an alternative diagnosis or the presence of advanced stage
*[[Thrombocytopenia]] suggests an alternative diagnosis or the presence of advanced stage
* Elevated [[uric acid]]
* Elevated [[uric acid]]
* Elevated [[histamine]] levels  
* Elevated [[histamine]] levels
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Fluorescence in situ hybridization|Fluoroscent insitu hybridization (FISH)]]
*[[Fluorescence in situ hybridization|Fluoroscent insitu hybridization (FISH)]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Imatinib]]
*[[Imatinib]]
* [[Dasatinib]]
*[[Dasatinib]]
* [[Nilotinib]]
*[[Nilotinib]]
* [[Bosutinib]]
*[[Bosutinib]]
* [[Ponatinib]]
*[[Ponatinib]]


* [[Cytarabine]]
*[[Cytarabine]]
* [[Cytarabine|HDAC]] (high-dose [[cytarabine]])
*[[Cytarabine|HDAC]] (high-dose [[cytarabine]])
* [[Hydroxyurea]]
*[[Hydroxyurea]]
* [[Busulfan]]
*[[Busulfan]]
* [[Busulfex]]
*[[Busulfex]]
* [[Stem cell transplantation]]
*[[Stem cell transplantation]]


|-
|-
Line 421: Line 444:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Various causes based on type:
* Various causes based on type:
** [[Hodgkin's lymphoma|Hodgkin's]]
**[[Hodgkin's lymphoma|Hodgkin's]]
** [[Non-Hodgkin lymphoma|Non-Hodgkin's]]
**[[Non-Hodgkin lymphoma|Non-Hodgkin's]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Fever]]
*[[Fever]]
* [[Weight loss]]
*[[Weight loss]]
* [[Lymphadenopathy]]
*[[Lymphadenopathy]]
* [[Hepatosplenomegaly]]
*[[Hepatosplenomegaly]]
* [[Night sweats]], constant [[fatigue]]
*[[Night sweats]], constant [[fatigue]]
* Purplish scaly rash in cases of [[cutaneous lymphoma]]
* Purplish scaly rash in cases of [[cutaneous lymphoma]]


| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Erythrocyte sedimentation rate|Elevated ESR]]
*[[Erythrocyte sedimentation rate|Elevated ESR]]
* [[C-reactive protein|Increased CRP]]
*[[C-reactive protein|Increased CRP]]
* [[Lactate dehydrogenase|Increased LDH]]
*[[Lactate dehydrogenase|Increased LDH]]
* [[Anemia of chronic disease]]
*[[Anemia of chronic disease]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Lymph node biopsy]]
*[[Lymph node biopsy]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
|-
|-
Line 444: Line 467:
* Aggregation and deposition of [[immunoglobulin light chains]] that are usually produced by [[plasma cell]] clones
* Aggregation and deposition of [[immunoglobulin light chains]] that are usually produced by [[plasma cell]] clones
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Nephrotic syndrome]] ([[peripheral edema]])
*[[Nephrotic syndrome]] ([[peripheral edema]])
* [[Restrictive cardiomyopathy]] ([[fatigue]], [[dyspnea]], [[syncope]])
*[[Restrictive cardiomyopathy]] ([[fatigue]], [[dyspnea]], [[syncope]])
* [[Peripheral neuropathy]] ([[numbness]], [[tingling]])
*[[Peripheral neuropathy]] ([[numbness]], [[tingling]])
* [[Hepatomegaly]] with elevated [[liver enzymes]]
*[[Hepatomegaly]] with elevated [[liver enzymes]]
* [[Macroglossia]]
*[[Macroglossia]]
* [[Purpura]]
*[[Purpura]]
* [[Bleeding diathesis]]
*[[Bleeding diathesis]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Typical green birefringence under polarized light after Congo red staining (appears in red under normal light)
* Typical green birefringence under polarized light after Congo red staining (appears in red under normal light)
Line 457: Line 480:
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Melphalan-prednisone/dexamethasone
* Melphalan-prednisone/dexamethasone
* Dexamethasone plus Cyclophosphamide-thalidomide  
* Dexamethasone plus Cyclophosphamide-thalidomide
* Stem cell transplantation
* Stem cell transplantation
|-
|-
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Gaucher's disease|Gaucher's Disease]]'''
| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''[[Gaucher's disease|Gaucher's Disease]]'''
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[GBA (gene)|GBA gene]] [[mutation]]
*[[GBA (gene)|GBA gene]] [[mutation]]
* Aberrant metabolism of [[glucocerebroside]] ([[lipid]])
* Aberrant metabolism of [[glucocerebroside]] ([[lipid]])
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Hydrops fetalis]]
*[[Hydrops fetalis]]
* Dry, scaly skin ([[ichthyosis]]) or other [[skin]] abnormalities
* Dry, scaly skin ([[ichthyosis]]) or other [[skin]] abnormalities
* [[Hepatosplenomegaly]]
*[[Hepatosplenomegaly]]
* Distinctive facial features
* Distinctive facial features
* [[Neurological disorder|Neurological problems]]
*[[Neurological disorder|Neurological problems]]
* [[Gall stones]]
*[[Gall stones]]
* [[Growth retardation]]
*[[Growth retardation]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Hypocholesterolemia]]
*[[Hypocholesterolemia]]
* [[Splenic]] nodules
*[[Splenic]] nodules
* [[Cytopenias]] (especially [[thrombocytopenia]])
*[[Cytopenias]] (especially [[thrombocytopenia]])
* Increased [[ferritin]] levels
* Increased [[ferritin]] levels
* Increased tartarate resistant acid phosphatase (TRAP) levels
* Increased tartarate resistant acid phosphatase (TRAP) levels
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Enzyme assay for [[glucocerebrosidase]]
* Enzyme assay for [[glucocerebrosidase]]
* [[DNA|DNA analysis]] for [[GBA (gene)|GBA mutation]]
*[[DNA|DNA analysis]] for [[GBA (gene)|GBA mutation]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Enzyme replacement therapy|Enzyme replacement]]
*[[Enzyme replacement therapy|Enzyme replacement]]
* [[Splenectomy]]
*[[Splenectomy]]
* [[Blood transfusion]]
*[[Blood transfusion]]
|-
|-
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF| |'''Organ System Involvement'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF| |'''Organ System Involvement'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Differential Diagnosis'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Causes'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Causes'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Features'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Features'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Laboratory Findings}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Gold Standard Test}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Therapy'''}}
|-
|-
| rowspan="7" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Cardiac Failure'''''
| rowspan="7" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Cardiac Failure'''''
Line 543: Line 566:
*  
*  
|-
|-
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Organ System Involvement'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Organ System Involvement'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Differential Diagnosis'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Differential Diagnosis'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Causes'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Causes'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Features'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Features'''}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Laboratory Findings}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Laboratory Findings}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|Gold Standard Test}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|Gold Standard Test}}
| style="background: #4479BA; width: 200px;" | {{fontcolor|#FFF|'''Therapy'''}}
| style="background: #4479BA; width: 200px;" |{{fontcolor|#FFF|'''Therapy'''}}
|-
|-
| rowspan="4" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Plasma Cell Dyscrasias'''''
| rowspan="4" style="padding: 5px 5px; background: #DCDCDC; font-weight: bold; text-align:center;" |'''''Plasma Cell Dyscrasias'''''
Line 563: Line 586:
*[[Anemia]]
*[[Anemia]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Anemia]]
*[[Anemia]]
* [[Thrombocytopenia]]
*[[Thrombocytopenia]]
* [[Leukopenia]]
*[[Leukopenia]]
* Decreased albumin (reversed albumin:globulin ratio)
* Decreased albumin (reversed albumin:globulin ratio)
* Increased serum creatinine, urea
* Increased serum creatinine, urea
Line 574: Line 597:
* Bence-Jones proteins in urine
* Bence-Jones proteins in urine
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Clonal plasma cells on bone marrow exam greater than equal to 10%  
* Clonal plasma cells on bone marrow exam greater than equal to 10%
 
AND
AND
* Any one of the following:
* Any one of the following:
** Evidence of end-organ damage
** Evidence of end-organ damage
Line 594: Line 619:
*Clonal [[plasma cell]] proliferation
*Clonal [[plasma cell]] proliferation
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Asymptomatic]]
*[[Asymptomatic]]
*  
*  
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Serum]] [[M protein]] of <3 g/L
*[[Serum]] [[M protein]] of <3 g/L
* Fewer than 10% [[plasma cells]] in the [[bone marrow]]
* Fewer than 10% [[plasma cells]] in the [[bone marrow]]
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Serum M protein (IgG or IgA) <3g/dl
* Serum M protein (IgG or IgA) <3g/dl
AND
AND
* Clonal bone marrow plasma cells < 10%
* Clonal bone marrow plasma cells < 10%
AND
AND
* No end-organ damage
* No end-organ damage
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
Line 616: Line 645:
*Clonal [[plasma cell]] proliferation
*Clonal [[plasma cell]] proliferation
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Asymptomatic]]
*[[Asymptomatic]]
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* [[Serum]] [[M protein]] of  greater than equal to 3 g/L
*[[Serum]] [[M protein]] of  greater than equal to 3 g/L
* Greater than 10% [[plasma cells]] in the [[bone marrow]]
* Greater than 10% [[plasma cells]] in the [[bone marrow]]
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage
* No evidence of [[bone]] or [[Organ (anatomy)|organ]] damage
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |
* Serum M protein (IgG or IgA greater than equal to 3 g/dl
* Serum M protein (IgG or IgA greater than equal to 3 g/dl
OR
OR
* Urinary M protein greater than equal to 500 mg/24 h
* Urinary M protein greater than equal to 500 mg/24 h
AND/OR
AND/OR
* Clonal bone marrow plasma cells 10-60%
* Clonal bone marrow plasma cells 10-60%
AND
AND
* No end-organ damage
* No end-organ damage
| style="padding: 5px 5px; background: #F5F5F5;" |
| style="padding: 5px 5px; background: #F5F5F5;" |

Revision as of 15:16, 30 October 2019

Primary amyloidosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Amyloidosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Primary amyloidosis differential diagnosis On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Primary amyloidosis differential diagnosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Primary amyloidosis differential diagnosis

CDC on Primary amyloidosis differential diagnosis

Primary amyloidosis differential diagnosis in the news

Blogs on Primary amyloidosis differential diagnosis

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for Primary amyloidosis differential diagnosis

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Overview

  • Differentiating Primary amyloidosis from Other Diseases
Organ System Involvement Differential Diagnosis Causes Clinical Features Laboratory Findings Gold Standard Test Therapy
Nephrotic Syndrome and Real Failure Primary (AL) Amyloidosis
  • Monoclonal plasma cell proliferation
  • Extracellular amyloid fibril deposition
  • Anasarca
  • Bleeding tendency
  • Swelling of lower limbs
  • Frothy urine
  • Chest pain
  • Numbness or tingling
  • Early satiety
  • Joint pains
  • Enlarged tongue
  • Taste loss
  • Hoarseness of voice
  • Hair loss
  • Increased erythrocyte sedimentation rate (ESR)
  • Increased alanine aminotrasnferase (ALT) and aspartate aminotrasnferase (AST)
  • Increased cardiac troponins
  • Increased brain natriuretic peptide (BNP)
  • Increased blood urea nitrogen (BUN) and creatininea
  • Proteinuria
  • Urinary hyaline and fatty casts
  • Hypercholesterolemia
  • Biopsy:
    • Diffuse glomerular deposition of amorphous hyaline material (nodular pattern), in mesangium (weakly staining with periodic acid-Schiff (PAS)
Diabetic Nephropathy
  • Hyperfiltration
  • Constriction of efferent arteriole
  • Microalbuminuria
  • Mesangial proliferation
  • Nocturia
  • Fatigue
  • Pruritis
  • Peripheral edema
  • Hyperglycemia (random plasma glucose ≥200 mg/dL)
  • Proteinuria
  • Glucosuria
  • HbA1C ≥6.5% (48 mmol/mol).
  • Biopsy:
    • PAS positive Kimmelstiel-Wilson nodules
Minimal Change Disease
  • Upper respiratory tract infection
  • Allergy to bee sting
  • NSAID
  • Gold
  • Penicillamine
  • Ampicillin
  • Mercury
  • Hodgkin's and non-Hodgkin's lymphoma
Focal Segmental Glomerulosclerosis
Fabry's Disease
Light Chain Deposition Disease
Membranous Glomerulonephritis
Fibrillary-Immunotactoid Glomerulopathy
Organ System Involvement Differential Diagnosis Causes Clinical Features Laboratory Findings Gold Standard Test Therapy
Polyneuropathy POEMS syndrome (Demyelinating)
Metabolic Syndrome (Axonal pathology)
Vitamin Deficiencies (Axonal Pathology)
Guillain-Barre Syndrome (Demyelinating)
  • Delayed F waves
  • Clinical diagnostic criteria (progressive weakness of more than two limbs, areflexia, and progression for no more than four weeks)
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) (Mixed axonal and demyelinatiing)
  • EFNS/PNS criteria
  • Koski criteria
Multifocal Motor Neuropathy
  • Progressive, asymmetric, distal and upper limb predominant weakness
  • No significant sensory abnormalities
  • Areflexia
  • Clinical criteria (EFNS/PNS):
    • Slowly progressive or step-wise progressive, focal, asymmetric limb weakness; i.e., motor involvement in the motor nerve distribution of at least two nerves for > 1 month.
    • No objective sensory abnormalities except for minor vibration sense abnormalities in the lower limbs
Organ System Involvement Differential Diagnosis Causes Features Laboratory Findings Gold Standard Test Therapy
Organomegaly (Hepatosplenomegaly and Lymphadenopathy) Malaria
Kala-azar
Infective Hepatitis
Chronic Myelogenous Leukemia (CML)
Lymphoma
Primary (AL) Amyloidosis
  • Typical green birefringence under polarized light after Congo red staining (appears in red under normal light)
  • Congo red staining
  • Melphalan-prednisone/dexamethasone
  • Dexamethasone plus Cyclophosphamide-thalidomide
  • Stem cell transplantation
Gaucher's Disease
Organ System Involvement Differential Diagnosis Causes Features Laboratory Findings Gold Standard Test Therapy
Cardiac Failure
Organ System Involvement Differential Diagnosis Causes Features Laboratory Findings Gold Standard Test Therapy
Plasma Cell Dyscrasias Multiple myeloma
  • Anemia
  • Thrombocytopenia
  • Leukopenia
  • Decreased albumin (reversed albumin:globulin ratio)
  • Increased serum creatinine, urea
  • Hypercalcemia
  • Elevated ESR
  • Normal-low alkaline phosphatase
  • RBC rouleaux formation
  • Bence-Jones proteins in urine
  • Clonal plasma cells on bone marrow exam greater than equal to 10%

AND

  • Any one of the following:
    • Evidence of end-organ damage
    • Hypercalcemia (>11 mg/dl)
    • Renal insufficiency
    • Anemia (Hb < 10 mg/dl)
    • Bone lesions
    • Greater than 1 lesions on MRI
Monoclonal gammopathy of undetermined significance (MGUS)
  • Serum M protein (IgG or IgA) <3g/dl

AND

  • Clonal bone marrow plasma cells < 10%

AND

  • No end-organ damage
  • Observation
Asymptomatic Plasma Cell Myeloma

(Smoldering and Indolent plasma cell myeloma)

  • Serum M protein (IgG or IgA greater than equal to 3 g/dl

OR

  • Urinary M protein greater than equal to 500 mg/24 h

AND/OR

  • Clonal bone marrow plasma cells 10-60%

AND

  • No end-organ damage
  • Observation
Plasmacytoma
  • On biopsy:
    • Solitary infiltrate of clonal plasma cells in bone (SBP) or soft tissue (EMP).
    • No evidence of infiltration by clonal plasma cells.
  • Negative skeletal survey plus MRI/CT spine and pelvis except for the solitary lesion.
  • Lack of hypercalcemia, renal insuffieciency, anemia, multiple bone lesions which would suggest MM
  • Diagnosis of exclusion
  • Radiotherapy
Skin Changes Scurvy